Skip to search formSkip to main contentSkip to account menu

S 32504

Known as: S-32504, S32504 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
RationaleDrug-discrimination studies have proven instructive in the characterization of psychotropic agents, a procedure applied… 
2006
2006
L‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor… 
Highly Cited
2004
Highly Cited
2004
In forced-swim tests in mice and rats, the novel D3/D2 receptor agonist S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4… 
Highly Cited
2004
Highly Cited
2004
These studies evaluated the potential antiparkinsonian properties of the novel dopamine D3/D2 receptor agonist S32504 [(+)-trans… 
2004
2004
S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] displayed marked affinity for… 
2004
2004
Anti-parkinsonian agents possessing both D(2) and D(3) receptor agonist properties are neuroprotective against 1-methyl-4… 
Highly Cited
2003
Highly Cited
2003
Recombinant, human dopamine D3 and D2 receptors form functional heterodimers upon co‐expression in COS‐7 cells. Herein, actions…